AC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy Rating
H.C. Wainwright Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $16
AC Immune Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and AC Immune SA (ACIU)
Promising Developments in AC Immune SA's ACI-7104 Program Drive Buy Rating
AC Immune Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Benitec Biopharma (BNTC), Bluebird Bio (BLUE) and AC Immune SA (ACIU)
H.C. Wainwright Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $16
AC Immune Analyst Ratings
Promising Interim Data and Safety Profile Justify Buy Rating for AC Immune's ACI-7104.056 Vaccine Trial
AC Immune Analyst Ratings
H.C. Wainwright Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $16
Optimistic Buy Rating on AC Immune Due to Promising Vaccine and Pipeline Developments
BTIG Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $8
AC Immune Analyst Ratings
H.C. Wainwright Maintains AC Immune(ACIU.US) With Buy Rating, Maintains Target Price $16
Analyst Issues Buy Rating for AC Immune SA on Promising Alzheimer's Treatment Prospects
Analysts' Top Healthcare Picks: AC Immune SA (ACIU), Equillium (EQ)
Buy Rating on AC Immune SA for Promising Alzheimer's and Parkinson's Vaccines
BTIG Starts AC Immune With Buy Rating, $8 Price Target